AGN 211745

Drug Profile

AGN 211745

Alternative Names: AGN-211745; AGN-745; Sirna 027

Latest Information Update: 16 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sirna Therapeutics
  • Developer Allergan
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration

Most Recent Events

  • 13 Feb 2007 Phase-II clinical trials in Age-related macular degeneration in USA (Intravitreous)
  • 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
  • 14 Aug 2006 Final results from a phase I clinical trial in patients with age-related macular degeneration have been added to the adverse events and Eye Disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top